Serum TSLP is a potential biomarker of psoriasis vulgaris activity
Authors El-Ghareeb MI, Helmy A, Al Kazzaz S, Samir H
Received 18 April 2019
Accepted for publication 20 June 2019
Published 30 July 2019 Volume 2019:9 Pages 59—63
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Professor Uwe Wollina
Mohamed Ibrahim El-Ghareeb,1 Afaf Helmy,1 Sally Al Kazzaz,2 Hanan Samir3
1Department of Dermatology, Zagazig University, Zagazig, Egypt; 2Dermatology, Zagazig General Hospital, Zagazig, Egypt; 3Clinical Pathology, Zagazig University, Zagazig, Egypt
Background: The proallergic cytokine, thymic stromal lymphopoietin (TSLP) may synergize with T cell–derived CD40 ligand (CD40L) to allow IL-23 production in patients with psoriasis. IL-23 is a central cytokine that mediates the inappropriate immune reaction in patients with psoriasis.
Objective: The aim of the study was to correlate serum level of TSLP with psoriasis severity.
Methods: The study was carried out on 53 patients with psoriasis. They were divided into mild, moderate, and severe according to PASI score. The patients’ ages ranged from 10 to 62 years. The patients included 29 males and 24 females. A total of 53 healthy subjects with matched age and sex served as control group. Blood samples were collected from the venous blood of the patients and control subjects then the serum was separated. The serum samples were immediately frozen at -20°C. Serum TSLP was measured by Sandwich Enzyme–linked Immunosorbant Assay (ELISA).
Results: There was a statistically very highly significant increase (p<0.001) in serum TSLP levels among the case group (1042.7±812.93) compared to the control group (314.21±220.78). There was also a statistically very highly significant increase (p<0.001) in serum TSLP levels with increased psoriasis severity estimated by PASI score.
Conclusion: In this study, we found that serum TSLP is elevated in psoriasis patients and is correlated with disease severity.
Keywords: TSLP, psoriasis vulgaris, serum biomarker
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]